Evusheld – COVID protection for the immunocompromised

Evusheld – COVID protection for the immunocompromised

What is Evusheld? Evusheld is monoclonal antibody prophylaxis for immunocompromised patients who did not get adequate COVID protection from the vaccines. It is developed by AstraZeneca and has received emergency use authorization from the FDA. Evusheld contains two long-lasting monoclonal antibodies, tixagevimab and cilgavimab that target surface spike protein of SARS-CoV2. It is designed to…